Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | MARS1 | P56192 | 2/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.37 |
| ▸ | SLC16A3 | O15427 | 2/20 | 0.36 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5533912 | 0.89 | CNR1 (0.51) | CNR1CNR2MARS1MEN1KMT2A | |
| SCHEMBL5522500 | 0.86 | CNR1 (0.48) | CNR1CNR2MARS1SLC16A3ANO1 | |
| SCHEMBL5526262 | 0.84 | MARS1 (0.63) | MARS1MEN1KMT2A | |
| SCHEMBL5529104 | 0.83 | CNR1 (0.51) | CNR1CNR2MARS1MALT1MEN1 | |
| SCHEMBL5521156 | 0.80 | ALDH1A1 (0.52) | MARS1MEN1KMT2A | |
| SCHEMBL5525005 | 0.78 | CNR1 (0.44) | CNR1CNR2SLC16A3SLC16A1 | |
| SCHEMBL27648461 | 0.77 | CNR1 (0.52) | CNR1CNR2MARS1MEN1KMT2A | |
| SCHEMBL5524327 | 0.77 | CNR1 (0.38) | CNR1CNR2ANO1 | |
| SCHEMBL5977928 | 0.77 | CNR1 (0.47) | CNR1CNR2ANO1 | |
| SCHEMBL5525584 | 0.76 | CNR1 (0.41) | CNR1CNR2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070219210-A1 | Amidopyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1698626-A1 | AMIDOPYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219210-A1 | Amidopyrazole Derivative | PTGER1, PTGS1, PTGER2 | CNR1 76/4885CNR2 43/4885MARS1 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.